Stratolaunch successfully completed its hypersonic test flight earlier this year. Image courtesy of Draper

With a recent air-launched test vehicle flight that came close to hypersonic speed, research company Draper has accelerated the potential for its flight technology.

Draper, a Cambridge, Massachusetts-based nonprofit, provided the crucial guidance, navigation, and control flight software for the flight. That guidance system was built on the same Draper technology that NASA has used in its Apollo mission, the international space station and space shuttle programs.

“In a broad sense, Draper has been working hypersonic since Apollo,” Rick Loffi, space systems program manager and lead executive for Draper’s Houston campus, tells InnovationMap.

The navigation software controlled the first powered test flight of an air-launched vehicle that approached the hypersonic threshold of Mach 5, or 3,800 miles per hour, or five times the speed of sound.

Stratolaunch successfully completed the flight of its TA-1 Talon test vehicle in the Mojave Desert in March. The California-based company designs and launches aerospace vehicles and technologies, providing access to a reusable hypersonic testing platform, according to its website. The historic test flight landed in the Pacific Ocean, and achieved successful ignition, acceleration and sustained altitude climb.

“The Draper software is really what’s stabilizing the vehicle during flight…and controlling it as it gets up into altitude and speed,” Brandon Jalbert, space systems program manager for Draper and team lead for Stratolaunch, says “so it’s not doing loop-de-loops, or getting unstable…blowing up in the atmosphere.”

Draper uses model-based design and algorithms in its software, and for the boost phase of the Talon test, Draper developed a novel algorithm, which built upon its previous work for NASA, Jalbert says.

Aerospace manufacturing companies like Boom and Hermeus stand poised to pick up where the Concorde left off, and are racing to implement and execute on accessible hypersonic and supersonic commercial technology.

The Concorde aircraft made supersonic, four-hour transoceanic flights a reality, but only for the very wealthy, and shut down in 2003.

Draper is not involved in any of those ventures to bring accessible supersonic flight back to the skies. Its primary focus with hypersonic will remain with deterrence and testing platforms, Jalbert says.

But the company’s technology “has applications everywhere from military to commercial activity,“ he says.

“Our focus is to solve complex challenges of national importance,” he says, “whether that’s…helping our commercial partners, or working on civil or military applications. That’s where we see ourselves being of value to the industry.”

With the harsh conditions involved in hypersonic flight, advancing the technology has its challenges.

“You’ve got to have proper hardware and electronics and sensors that can operate within those conditions,” Jalbert says.

Draper originated in 1932 when engineer Charles Stark Draper founded what eventually became the Instrumentation Lab at MIT.

His work on inertial navigation theory paved the way for the use of the autopilot in today’s commercial jets. The lab was divested by MIT in the 1970s, and became a nonprofit. Draper has long been a government contractor and has worked on many military projects, dating to WWII.

Draper in 2023 secured the $2.2 billion renewal of a long-standing contract with the U.S. Navy to provide the guidance system for the submarine-launched Trident II D-5 missile.

The U.S. government has shown a growing interest in the development of hypersonic weapons systems, as Russia and China have developed advanced capabilities.

The Pentagon’s budget request for hypersonic research for fiscal year 2025 was $6.9 billion, up from $4.7 billion for 2023, according to a recent U.S. Naval Institute report.

“There’s a big shift, in deterrence, as well as offensive, on hypersonic,” Jalbert says.

However, the Defense Department has not yet acquired hypersonic weapons, according to the report, but is developing prototypes and testing.

Draper has a long, celebrated history with NASA, and its Houston office is housed at Johnson Space Center. Draper's presence in Houston dates back to the 1960s, Loffi says.

From the Apollo missions to the space station and now the Artemis program, which aims to land the first person of color and the first woman on the moon by 2026 on its Orion spacecraft, Draper has partnered with NASA every step of the way, providing its navigation system for space flight.

“Right now, our biggest customer within NASA is the Orion program,” Loffi says, with approximately 15 of the 20-person Houston office working on the project, in collaboration with the company’s Cambridge colleagues.

Draper's Houston office is working on NASA's Orion program. Photo via NASA

The company is also working with NASA on lunar landing technology and sub-orbital experiments, as well as the propulsion element and Gateway space station for Artemis.

Amazon founder Jeff Bezos’s aerospace manufacturing company Blue Origin is also partnering with Draper to develop the Artemis human landing system.

Neither Loffi nor Jalbert aspired to go into outer space themselves, but rather to provide solutions to make that possible. Human spaceflight has been a lifelong passion for Loffi.

While he had lots of job opportunities after graduating from Purdue University with a degree in electrical engineering, Loffi chose NASA.

“I wasn’t that person who grew up dreaming of becoming an astronaut,” Loffi says. “I was old enough to see the Apollo 11 moon landing, and it did inspire me.”

His work at NASA began after the space shuttle Challenger explosion, in 1986. He was part of the agency’s effort to return to space flight, and worked on space station development, before joining Draper in 2011.

Jalbert, a graduate of Northeastern University, says his early work at Draper “lit the fires for my interest in space.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

Houston business mogul Tilman Fertitta acquires Caesars in $17.6B deal

Money Moves

Houston billionaire Tilman Fertitta may currently be serving as America’s ambassador to Italy, but his company is as busy as ever. Fresh off its move to revive the Houston Comets WNBA franchise, his company, Fertitta Entertainment, has announced a $17.6 billion deal to acquire Caesars Entertainment, Inc.

Speculation about the deal has been circulating since at least March, according to various media reports. The deal combines Fertitta’s well-known Golden Nugget casino brand with all of the properties in the Caesars’ portfolio, including Las Vegas hotels Caesars Palace, Harrah's, Paris Las Vegas, Planet Hollywood, Horseshoe, The LINQ Hotel, Flamingo, and The Cromwell.

Overall, the combined company will include 60 domestic casino resorts and gaming facilities; online gaming including sports betting, iCasino, and Caesar’s online poker platform; retail sports betting at over 200 third-party locations through the William Hill brand; and over 550 Fertitta Entertainment outlets, including more than 450 Landry's full-service restaurants across America. The companies will combine their loyalty programs, Caesars Rewards, Golden Nugget's 24 Karat Select Club, and Landry's Select Club.

The terms will see Caesars’ shareholders receive $31 per share. Fertitta Entertainment will also acquire approximately $11.9 billion of Caesars' outstanding debt.

The transaction will be financed through a combination of equity contributed by Fertitta Entertainment, assumed Caesars' debt, and new committed debt financing arranged by a group consisting of 10 banks. It is subject to approval by Caesars’ shareholders and government regulators.

Fertitta Entertainment is the Houston-based company behind a diverse array of hospitality businesses, including The Golden Nugget, The Post Oak Hotel, River Oaks District, the Kemah Boardwalk, and Houston’s Downtown Aquarium.

It also operates a number of prominent restaurant brands, including Mastro's Restaurants, Del Frisco's Double Eagle Steakhouse, Morton's The Steakhouse, The Palm, McCormick & Schmick's, Landry's Seafood House, The Oceanaire Seafood Room, and Saltgrass Steak House.

---

This article first appeared on CultureMap.com.

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.